Lymphoma cells mobilize many mechanisms to evade the immune system. There is substantial evidence that CD4 1 CD25 1 regulatory T cells (Tregs) play a key role in the control of immune evasion. Tregs can transfer cyclic adenosine monophosphate (cAMP) to effector T cells, suggesting an association between Tregs' immune-evasion role and the intracellular cAMP pathway. In this study, we used A20 B-cell lymphoma mice as aggressive tumor models to investigate the mechanism of the depletion of Tregs by low-dose cyclophosphamide (CY, 20 mg/kg). The tumor-bearing mice had longer survival times and slower tumor growth rates following treatment with CY, but its effects were temporary. Along with the depletion of Tregs by low-dose CY treatment, the expression of interleukin-2 (IL-2) in T effector cells increased, and intracellular cAMP concentrations in immune cells decreased. Our study demonstrates the ability of low-dose CY to reverse Tregs-mediated immune evasion in a mouse model. The changes in intracellular cAMP concentrations correlated with the upregulation of effector T cells and the downregulation of Tregs, indicating the close association of cAMP analogs and low-dose CY in the immune therapy of B-cell lymphoma.
INTRODUCTION
The pathogenesis of lymphoma involves the immune system and immune escape. Lymphoma cells utilize direct and indirect mechanisms to escape from immune surveillance, including the low expression of T-cell receptors, inefficient priming, the defective homing or cytolysis of immune cells, and the cell-mediated suppression of antitumor T cells. 1, 2 Many immunological studies have confirmed that CD4 1 CD25 1 FOXP3 1 regulatory T cells (Tregs), which possess specialized suppressive functions, play a key role in the control of tumor immunity and immune evasion.
3,4 Since Bui et al. demonstrated the accumulation of Tregs within tumors, several human tumors have been found to exhibit increased levels of Tregs, 5, 6 suggesting that immunotherapy involving Tregs suppression may be effective in lymphomas. 7, 8 Many studies have focused on the removal of Tregs in animal models, resulting in the improved function of CD4 1 effector T cells (Teff cells) and the enhancement of the antitumor response. 9 These observations suggest that the success of immunotherapy for cancer may ultimately depend on the balance between Treg and Teff cells. 10, 11 Increasing evidence indicates that Tregs mediate immunosuppressive functions through the utilization of many soluble mediators and cell-to-cell contact, further inducing a positive feedback loop. 1 Bopp et al. 12 showed that natural Tregs can transfer cyclic adenosine monophosphate (cAMP) to Teff cells, resulting in increased intracellular cAMP concentrations in Teff cells. 12 Further investigations have shown that phosphodiesterase, which is the enzyme that accelerates the turnover of cAMP, is upregulated in activated Teff cells, improving T cell-based tumor clearance. [13] [14] [15] [16] Huang et al. verified that miR-142-3p restricts cAMP production in Teff cells and Tregs. 17 The second messenger cAMP is a potent inhibitor of interleukin-2 (IL-2) synthesis in T cells. 18 Therefore, Tregs may suppress the antitumor immune response through the intercellular transport of cAMP and the activation of the cAMP-protein kinase A signaling pathway, 19 suggesting a new approach for immune therapy involving alterations in intracellular cAMP.
In recent years, many immunologists have investigated the depletion of Tregs by low-dose cyclophosphamide (CY) 20 in tumors and certain autoimmune conditions. CY, which is a nitrogen mustard compound, is widely used in the treatments of leukemia, lymphomas and solid tumors, and exhibits effective cytotoxicity against tumor cells. However, low-dose CY has been shown to suppress tumor immunity in hosts by selectively depleting CD4 1 CD25 1 Tregs, and the antitumor effects of low-dose CY are immune-mediated. [21] [22] [23] In fact, there has been no investigation into the role and mechanism of low-dose CY therapy in lymphoma in animal models or human patients.
Given that Tregs inhibits tumor immunity and that CY has a paradoxical effect on the immune system, we hypothesized that low-dose CY may contribute to the immune therapy of lymphoma. To prove this hypothesis, we used the A20 B-cell lymphoma mouse as an aggressive tumor model to delineate the role of Tregs in tumor development and to investigate their inhibition by low-dose CY. Moreover, changes in intracellular cAMP concentrations following CY treatment were particularly monitored to reveal a new therapeutic target for lymphoma.
MATERIALS AND METHODS

Mice and cell lines
All animal experiments were performed in accordance with the guidelines of the Committee on the Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (DHEW publication no.
[NIH] FS-23). Six-week-old male BALB/c mice were purchased from the Experimental Animal Center of Shandong University (Jinan, China). The mice were kept in a specific pathogen-free room with alternating 12-h dark-light cycles. The mouse B-cell lymphoma cell line, A20, was a generous gift from Zhongshan University (Guangzhou, China). This tumor cell line is derived from a spontaneous reticulum cell neoplasm in BALB/c mice. 1 The A20 cells were cultured in RPMI 1640 medium (Hyclone, Logan, UT, USA) that was supplemented with 10% heat-inactivated fetal bovine serum, 100 U/ml penicillin, 100 mg/ml streptomycin and 2 mM L-glutamine at 37uC in a 5% CO 2 -humidified incubator.
Antibodies and reagents
The cyclophosphamide 20 was purchased from Sigma-Aldrich (St Louis, MO, USA) and dissolved in 0.9% normal saline (NS) according to the manufacturer's instructions. The fluorescein isothiocyanate anti-mouse CD4 monoclonal antibody (mAb) and phycoerythrin anti-mouse CD25 mAb were purchased from eBioscience (San Diego, CA, USA). A Dynabeads FlowComp Mouse CD4 1 CD25
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Treg Cells Kit was obtained from Invitrogen (Carlsbad, CA, USA). A cAMP Concentration Assay kit was purchased from BioVision (Mountain View, CA, USA). Rat anti-mouse FOXP3 antibodies were obtained from eBioscience. Rabbit anti-mouse b-actin antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Tumor transplantation and therapy
At day 27, A20 lymphoma cells were implanted into BALB/c mice at concentrations of 5310 6 cells per mouse in 100 ml of RPMI 1640 by subcutaneous injection into the left flanks. Beginning on day 0, which is when the tumors reached their largest diameters of 5-7 mm, the tumor-bearing mice received 20 mg/kg of CY or NS via the intraperitoneal route each week. We divided the mice into four groups: BALB/ c, tumor, tumor1NS and tumor1CY. There were six mice in each group. The tumor growth and tumor-bearing survival rates were observed. The mice were killed at 4, 8, 12 and 14 days following the CY treatment. The inguinal, auxiliary and cervical lymph nodes were harvested. Lymphocytes were extracted, and single-cell suspensions were prepared as previously described. 24 At least three independent experiments were performed for each assay.
Flow cytometric analysis
The percentages of Tregs in the single-cell suspensions were measured by staining with the fluorescein isothiocyanate anti-mouse CD4 mAb and phycoerythrin anti-mouse CD25 mAb. Briefly, an aliquot of 1310 5 cells was incubated with fluorescein isothiocyanate anti-mouse CD4 mAb and phycoerythrin anti-mouse CD25 mAb for 15 min at room temperature in the dark. Next, the cells were washed and immediately analyzed using a flow cytometer (Epics XL-4; Beckman Coulter Inc., Fullerton, CA, USA), and data were analyzed with the tetraONE software. Tregs were added to 1 ml 0.1 N HCl to inactivate the esterases and then transferred to centrifuge tubes and centrifuged at top speed for 10 min. The supernatants were either assayed directly or stored at 280uC. After incubation and washing, the amounts of cAMP-HRP that were bound to the plates were determined by measuring the HRP activities at OD450 nm. The intensities at OD450 nm were inversely proportional to the cAMP concentrations in the samples. The detection sensitivity improved significantly with the use of the acetylation procedure.
Real-time quantitative polymerase chain reaction (PCR)
Total RNA was extracted from the lymphocytes and CD4
1 T cells with TRIzol (Invitrogen) according to the manufacturer's instructions. Total RNA (0.5 mg) was used for the reverse transcription of cDNA. Quantitative PCR was performed with the ABI 7500 PCR Instrument (PerkinElmer, Waltham, MA, USA) using SYBR Premix Ex Taq (Takara, Dalian, China). Primers used in this study were as follows: mouse IL-2: forward 59-GCATGCAGCTCGCATCCTGTG-39, reverse 59-TTCTGTGGCCTGCTTGGGCA-39; mouse FOXP3: forward 59-CCCATCCCCAGGAGTCTTG-39, reverse 59-ACCATGACTAG-GGGCACTGTA-39; and mouse ACTIN: forward 59-GGCTG-TATTCCCCTCCATCG-39, reverse 59-CCAGTTGGTAACAATG-CCATGT-39. Mouse b-actin mRNA was used for normalization to ensure equal amounts of starting RNA.
Western blot analysis
Total protein was extracted from lymphocytes using RIPA and 1% PMSF (Shenergy Biocolor, Shanghai, China). The total protein (40 mg) was subjected to SDS-PAGE followed by a western blot using a 1 : 500 dilution of the anti-mouse FOXP3 antibody (Abgent, San Diego, CA, USA). Single immunoreactive bands at 50 kD for FOXP3 were observed using the ImageQuant LAS 4000 mini (Fujifilm, Tokyo, Japan). The FOXP3 protein was measured by assessing the levels of b-actin protein as an internal standard. The band images were analyzed by Multi Gauge Version 3.0 (Fujifilm).
Statistical analyses SPSS 12.0.1 for Windows (SPSS, Inc., Chicago, IL, USA) and GraphPad Prism 4 (GraphPad Software, San Diego, CA, USA) were used for the statistical analyses, which included two-tailed Student's ttest, and the results are reported as the mean6s.d. of the values (obtained from at least three independent experiments). All of the differences were considered to be statistically significant when P,0.05. 
CD25
1 Tregs out of the total lymphocytes were analyzed for each group of mice; they were observed to be 7.68%, 11.9%, 8.59%, 7% and 10.8% for the BALB/c, tumor, tumor1CY4d, tumor1CY8d and tumor1CY14d groups, respectively (Figure 3a) . The percentage of Tregs in the tumor1CY group remained at approximately 11% after day 14. The tumor1NS mice were analyzed at the same time, but the NS treatment did not alter the percentage of Tregs (data not shown). We further calculated the ratios of Tregs to CD4 1 cells from three independent experiments. The difference between the BALB/c and tumor groups was significant (13.87%60.4667% vs.
23%60.5774%, P50.003), indicating that the A20 tumors increased their ratios of Tregs/CD4 1 cells. Following CY therapy, the Treg/CD4 1 proportions decreased transiently. There was a significant difference observed between the tumor and CY8d groups (23%60.5774% vs. 13.87%60.5925%, P50.0004). At day 14, the Treg/CD4 1 proportions increased to 23.77%60.5925%, slightly exceeding the levels that were exhibited by the tumor group (Figure 3b) .
To analyze the expression of FOXP3, which is the Treg-specific marker, we performed real-time PCR and western blotting. Changes in the mRNA expression and protein levels are shown in Figure 3c and e, respectively. b-actin was used to assess cell equivalency among the samples (Figure 3d) . The FOXP3 mRNA expression significantly differed between the tumor and BALB/c groups (*P50.0164). At day 8, the mRNA expression of FOXP3 decreased to minimum levels (***P,0.001, CY8 group vs. tumor group). However, the expression levels exceeded the pretreatment levels on day 14, indicating the transient effect of low-dose CY on FOXP3 mRNA expression. We further measured FOXP3 protein levels in the different groups of BALB/c mice with or without A20 cells and low-dose CY (Figure 3e) . By calculating the ratio of the intensities of the FOXP3 and b-actin bands, we found 
003). The ratio of Treg/CD4
1 cells in the tumor and CY8 groups was significantly different (the tumor group vs. the CY8 group, P50.0004), and levels in the CY14 group slightly exceeded those in the tumor group (tumor group vs. CY14 group, P50.4056). (c) Equivalent numbers of the lymphocytes at the indicated time points were harvested, and total RNA was extracted for real-time PCR. All data are representative of three independent experiments and expressed as the mean6s.d. The FOXP3 mRNA expression of specified groups significantly differed (tumor group vs. BALB/c group, *P50.0164; CY8 group vs. tumor group, ***P,0.001). (d, e) Equivalent numbers of lymphocytes were harvested at the indicated time points with or without A20 cells and CY, and total protein was extracted for western blot analyses. d shows the intensity of the FOXP3 band normalized to the b-actin band. e shows the CY treatment transiently reduced the protein expression of FOXP3. The changes in protein levels were consistent with the mRNA changes that are shown in c. CY, cyclophosphamide; mAb, monoclonal antibody; PCR, polymerase chain reaction; Treg, regulatory T cell. 
DISCUSSION
Lymphoma development and progression involves a complex process of genetic alterations in tumor cells in addition to abnormalities in immunosurveillance. Developing effective immunotherapeutic approaches to reverse immune evasion is important for the treatment of lymphomas. Tregs are emerging as key regulators of tumor immune evasion. [25] [26] [27] In our study, we established an aggressive transplantable murine lymphoma model with A20 cells and investigated the effects of low-dose CY on tumor immunity. Treatment with 20 mg/kg/week of CY inhibited tumor growth, increased the survival rates of A20 tumorbearing BALB/c mice, and ultimately increased the IL-2 secretion of CD4
1 Teff cells. The IL-2 expression in the Teff cells was affected by the Tregs and thus was used as an indicator of Treg depression. 28 Our data showed that the IL-2 increase was synchronized with a FOXP3 decrease, which strongly suggested that the reduction of Tregs by lowdose CY enhances immune activation, resulting in improved antitumor immunity.
Cyclophosphamide appears to be an exceptional chemotherapeutic agent, 29 and its paradoxical ability to suppress and enhance immune responses has been well established. 30 Low-dose CY (20 mg/kg or less) modulates the immune system in hosts by selectively depleting Tregs, whereas in nude mice, the suppressive effects of low-dose CY were no longer observed. 22 In our lymphoma mouse model, we confirmed the ability of low-dose CY to reverse Tregs-associated immune evasion.
Our study demonstrates that low-dose CY transiently decreases intracellular cAMP concentrations in immune cells. cAMP is a ubiquitous intracellular second messenger that affects cell physiology, including hormone release and cell differentiation. 31 Recent studies have reported a significant role of adenosine in mediating Treg function. The anti-immune/inflammatory response is associated with increased intracellular cAMP, which inhibits the cytokine responses of all immune cells, providing a paracrine feedback mechanism to signal the presence of an immunological challenge. 32, 33 Low levels of intracellular cAMP in immune cells are essential to the induction of an immune response. The transport of cAMP between Tregs and other T cells has been identified and confirmed in several studies. 12, 34, 35 Our study showed that low-dose CY changes the intracellular cAMP concentrations of immune cells, indicating that the cAMP signaling pathway is critical to Treg-mediated immune evasion and CY-induced Treg suppression. Furthermore, our data demonstrate that cAMPdependent signal transduction directly attenuates the production of IL-2 in CD4 1 Teff cells. Many studies have demonstrated that cAMP is a potent inhibitor of IL-2 production and the subsequent proliferation of CD4 T cells. 12, 33 This finding was later confirmed by the identification of a cAMP-inducible transcriptional repressor that is termed the 'inducible cAMP early repressor'. 36, 37 Inducible cAMP early repressor attenuates IL-2 expression by competitively binding to the transcription factor cAMP response element-binding protein. 38 Our study confirms the correlation between the cAMP signaling pathway and CY treatment, and our findings appear to contradict the clinical efficacy of the combination of chemotherapy and immunotherapy for the treatment of lymphoma patients.
Overall, our study shows the increased removal of Tregs due to CYenhanced antitumor immunity against B-cell lymphoma. However, the absolute numbers and FOXP3 expression levels of the Tregs were Following the tumor challenge, the change in IL-2 mRNA expression that was observed in the Teff cells was significantly different (tumor group vs. control group, P,0.001); this was also observed following the CY treatment (CY4 group vs. tumor group, P50.0168; CY8 group vs. tumor group, P,0.001; CY12 group vs. tumor group, P,0.001). CY, cyclophosphamide; MACS, magnetic-activated cell sorting; Teff, effector T.
cAMP involvement in CY-reversed immune evasion AX Dou et al 486 restored or even exceeded the initial levels by day 14, indicating that the effects of CY were transient in vivo. 39 The administration of immunostimulating compounds during the period of Treg inhibition could theoretically allow for enhanced antitumor immune responses. 40 The transient role of CY may be attributed to three conditions. First, in the early phases of tumor development, A20 cells may rely on Tregs to control the initial activation events and mediate immune evasion mechanisms. 1, 41 Various immune evasion mechanisms may complement and/or augment the roles of Tregs in tumor progression. Therefore, immunotherapeutic approaches targeting Treg elimination in cancer patients should consider the type and stage of the tumor and its associated immune evasion mechanisms.
Second, the therapeutic efficacy of Treg depletion in various preclinical models is shown to depend upon cooperation with other immunotherapeutic ingredients, such as IL-12 gene therapy, dendritic cell vaccines, heat shock proteins and photodynamic therapy. 20, 40, [42] [43] [44] In cancer patients, immunotherapy that specifically targets Tregs may fail or be insufficient to reverse tumor growth, depending on the cancer type. The efficacy of an immunotherapy depends upon its ability to effectively overcome immune evasion mechanisms and generate new antitumor responses and/or upregulate the existing responses. Feinerman et al. 45 suggested a tug-of-war hypothesis, in which there is competition for IL-2 between Tregs and Teff cells. Although our study used the down-regulation of IL-2 as an indicator of Treg function, it is unclear whether IL-2 is the primary molecular target of suppression.
Finally, the cAMP signaling pathway influences the pathogenesis of lymphoma and apoptosis-inducing therapies. Research has demonstrated that increased intracellular cAMP levels induce cell-cycle arrest and apoptosis in several types of lymphoma cells. 46 In chemoresistant diffuse large B-cell lymphoma patients with high phosphodiesterase 4B (PDE4B) levels, intracellular cAMP concentrations are low, and the cAMP pathway is impaired. 47 Due to their potential roles in inhibiting proliferation, promoting apoptosis and regulating cell cycles, cAMP analogs and PDE4B inhibitors are good candidate agents for lymphoma therapy. 48 Low cAMP concentrations are required by Teff cells; therefore, the local redistribution of intracellular cAMP between the immune and lymphoma cells is necessary for the therapy to be effective. The cAMP signaling pathway also participates in CY metabolism in the liver. 49, 50 The appropriate sequential administration of CY and cAMP analogs/PDE4B inhibitors to lymphoma patients may be an effective approach for cancer therapy. It should be emphasized that the dose conversion between mice and humans is important for obtaining an equivalent murine dose. The low-dose CY (20 mg/kg/week) treatment that we used in this study corresponds to approximately 200 mg/m 2 in humans. 22 Furthermore, 200-300 mg/m 2 CY has been widely used as an immunopotentiating agent in immunotherapy for cancers and autoimmune diseases. 23, 30, 51, 52 Further studies on the CY-mediated suppression of Tregs in human lymphomas will help us to better understand Treg physiology and develop novel strategies for lymphoma treatment.
Taken together, our data provide direct evidence for the critical role of Tregs in lymphoma immune evasion and reveals the importance of the cAMP pathway in CY treatment, which reverses immune evasion. The cAMP pathway participates in the PI3K-AKT-mTOR axis, which is used by Tregs to control FOXP3 levels. 53, 54 With their potential roles in reversing tumor immune evasion and promoting apoptosis, and due to the potential clinical cooperation between the cAMP pathway and the CY-Tregs pathway, cAMP analogs/PDE4B inhibitors and lowdose CY may be good candidate agents for lymphoma therapy. 
